Phase II study of pegylated liposomal doxorubicin (Caelyx™) as induction chemotherapy for patients with squamous cell cancer of the head and neck

European Journal of Cancer

Volumn 37, Issue 16, 2001, Pages 2015-2022

  Harrington, K J ^a,b   Lewanski, C ^c   Northcote, A D ^c   Whittaker, J ^d   Peters, A M ^a   Vile, R G ^a,b   Stewart, J S W ^c  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b MAYO CLINIC   (United States)

^c CHARING CROSS HOSPITAL   (United Kingdom)

^d ALZA CORPORATION   (United States)

Author keywords

Doxorubicin; Head and neck cancer; Pegylated liposome; Radiotherapy; Response; Toxicity

Indexed keywords

DOXORUBICIN;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG INDUCED DISEASE; DRUG RESPONSE; DRUG SCREENING; DRUG TARGETING; FEMALE; HEAD CANCER; HUMAN; MALE; NAUSEA; NECK CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION INJURY; SQUAMOUS CELL CARCINOMA; VOMITING;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CHEMOTHERAPY, ADJUVANT; DOXORUBICIN; FEMALE; FOLLOW-UP STUDIES; HEAD AND NECK NEOPLASMS; HUMANS; LIPOSOMES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NECK; TREATMENT OUTCOME;

EID: 0034774382     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(01)00216-7     Document Type: Article

References (33)

1. Treatment of cancer with radiation and drugs
2. Radiation therapy alone or with concurrent low-dose daily either cisplatin or carboplatin in locally advanced unresectable squamous cell carcinoma of the head and neck: A prospective randomized trial
3. An overview of randomised controlled trials of adjuvant chemotherapy in head and neck cancer
4. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: Three meta-analyses of updated individual data
5. Cyclophosphamide, adriamycin, and cis-diamminedichloroplatinum (II) in the treatment of patients with advanced head and neck cancer
6. A phase II clinical trial of the combination mitomycin C, adriamycin, and cis-diamminedichloroplatinum in patients with advanced upper aerodigestive cancer
7. A phase II clinical trial of 4′-epi-doxorubicin in advanced solid tumors
8. Phase II trial of 4′-epi-doxorubicin in advanced carcinoma of head and neck origin
9. Pegylated liposome encapsulated doxorubicin and cisplatin enhance the effect of radiotherapy in a tumor xenograft model
10. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polethylene-glycol coated liposomes
11. Amphipathic polyethyleneglycols effectively prolong the circulation times of liposomes
12. Pharmacokinetics and therapeutics of sterically stabilised liposomes in mice bearing C-26 colon carcinoma
13. Microscopic localisation of sterically stabilised liposomes in colon carcinoma-bearing mice
14. Extravasation and transcytosis of liposomes in Kaposi's sarcoma-like dermal lesions of transgenic mice bearing the HIV tat gene
15. Doxorubicin encapsulated in sterically stabilised liposomes for the treatment of a brain tumor model: Biodistribution and therapeutic efficacy
16. Tissue distribution and therapeutic effect of intravenous free or encapsulated liposomal doxorubicin on human prostate carcinoma xenografts
17. Comparative study of the anti-tumor activity of free doxorubicin and polyethylene glycol-coated liposomal doxorubicin in a mouse lymphoma model
18. Pharmacokinetics and antitumor activity of epirubicin encapsulated in long-circulating liposomes incorporating a polyethylene glycol-derivatized phospholipid
19. Therapy of mouse mammary carcinomas with vincristine and doxorubicin encapsulated in sterically stabilised liposomes
20. Tumor uptake of doxorubicin in polyethylene glycol-coated liposomes and therapeutic effect against a xenografted human pancreatic carcinoma
21. Pegylated liposome encapsulated doxorubicin and cisplatin in the treatment of head and neck xenograft tumors
22. Effective targeting of solid tumours in patients with locally advanced cancers by radiolabelled pegylated liposomes
23. Phase I study of Caelyx (doxorubicin HCL, pegylated liposomal) in recurrent or metastatic head and neck cancer
24. The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin
25. 2
26. Twice-a-day radiation therapy for cancer of the head and neck
27. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: First report of RTOG 9003
28. Randomised comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma
29. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma: Results of a randomised phase III clinical trial
30. Liposomal doxorubicin and conventionally fractionated radiotherapy in the treatment of locally advanced non-small-cell lung cancer and head and neck cancer
31. 111In-DTPA-labelled pegylated liposomes in a human tumour xenograft model
32. Sterically stabilised liposomes labeled with Indium-111 to image focal infection
33. Labelled Stealth® liposomes in experimental infection: An alternative to leukocyte scintigraphy?